VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a global leader in epigenetics or gene regulation, is pleased to announce that Future development of Apabetalon will focus on the prevention and treatment of post-COVID-19 conditions. The company’s new focus on patients with Post COVID-19 condition (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients It reflects an attractive opportunity to benefit COVID-19 patients in the United States and guidance from the United States. Food and Drug Administration.
Media snippets accompanying this announcement are available by clicking the image or link below.
For more information, watch the InvestmentPitch Media video that provides additional information about this news and the company. You can watch the video at “”.Investment Pitch.com“When”Youtube”. If these links are not enabled, please visit the following URLs: www.InvestmentPitch.com Type “Resverlogix” in the search box.
After the recent FDA meeting, Dr. Michael Sweeney, senior vice president of clinical development at Resverlogix, said:We thank the FDA for the feedback and suggestions provided at the recent Type C meeting and look forward to continuing to work with regulatory agencies in evaluating the safety and efficacy of apabetalon in the treatment of post-COVID-19 conditions.”
According to recent estimates from the CDC, one in three adults in the United States could experience long-term COVID-19 after contracting it. A recent study of more than 13 million people found that vaccination against COVID-19 could help reduce her risk of COVID over the long term, but only 15%.
Dr. Michael Sweeney added:Patients around the world are coping with persistent symptoms of COVID-19, often weeks to months after initial infection. There are currently few treatment options available for this group of people, and apabetalon has great potential to help them. known, and cardioprotective effects of apabetalon have been seen in other high-risk populations.”
Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and a world leader in epigenetics (gene regulation) developing best-in-class therapeutics for the benefit of patients with chronic diseases The goal is to Resverlogix is developing a new class of epigenetic therapeutics designed to modulate the expression of disease-causing genes.
Apabetalon (RVX-208) is a first-in-class small molecule therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extraterminal) inhibitor that helps prevent and treat disease progression by regulating the expression of disease-causing genes. The extensive role of BET proteins in the human body allows Apabetalon to simultaneously target multiple disease-related biological processes and treat chronic diseases while maintaining a well-described safety profile. It leads to new ways.
Apabetalon has been granted Breakthrough Therapy Designation by the FDA and has safety data in well over 4,200 patient-years across 10 clinical trials, making it the only one in its class with an established safety record in human clinical trials. It’s a drug. Studies published in prominent scientific journals, including Cell, show that Apabetalon may act against her COVID-19 through a unique dual mechanism. Second, by avoiding an excessive inflammatory response that can cause severe and permanent organ damage.
Investigational treatments could potentially reduce the severity and duration of post-COVID-19 conditions. Apabetalon’s unique dual mechanism may show efficacy against the new her COVID-19 variant, and also means it may even help fight other viruses. The company has finalized a Phase 3 trial protocol for apabetalon in his PCC and will begin the trial in the first half of 2023, subject to all necessary regulatory and other applicable approvals and securing the necessary resources It’s a schedule.
Resverlogix is partnering with EVERSANA™, a pioneer of next-generation commercial services for the global life sciences industry, to support the rapid global commercialization of Apabetalon against COVID-19. EVERSANA™ currently leads clinical outreach and advocacy for Apabetalon.
The stock is trading at $0.21. for more information. Please visit the company website. www.resverlogix.comor contact the company at 403-254-9252 or email [email protected].
The information in this InvestmentPitch Media Ltd video is for viewer information. Resverlogix paid him no more than $2,000 in cash to produce the current news release in video format. Company information is based on publicly available information. Information provided by InvestmentPitch Media Ltd. through its media services is not to be construed as a recommendation, offer or offer to buy or sell securities and is provided solely as an information media service. InvestmentPitch Media Ltd makes no warranties or obligations as to the accuracy or completeness of this information. All due diligence must be done by the viewer or their financial advisor. Investing in securities is speculative and involves risk.
About Investment Pitch Media
Investment Pitch Media harnesses the power of video, combined with its wide distribution, to put your company’s story ahead of thousands seeking recognition and funding from the financial industry. The company specializes in producing short videos based on important news releases, research reports and other content of interest to investors.
A video from InvestmentPitch Media discusses Resverlogix and its focus on the future development of Apabetalone for the prevention and treatment of post-COVID-19 conditions. Canadian Business Journal
Source link A video from InvestmentPitch Media discusses Resverlogix and its focus on the future development of Apabetalone for the prevention and treatment of post-COVID-19 conditions. Canadian Business Journal